Arvinas, Inc. (NASDAQ:ARVN) Given Average Rating of “Moderate Buy” by Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has received a consensus recommendation of “Moderate Buy” from the fifteen ratings firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $63.50.

ARVN has been the topic of a number of research analyst reports. BTIG Research initiated coverage on Arvinas in a report on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a research note on Thursday, December 12th. BMO Capital Markets cut their target price on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and set a $87.00 price target on shares of Arvinas in a research report on Wednesday, December 11th. Finally, Oppenheimer lowered their price objective on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st.

Arvinas Trading Up 1.9 %

Shares of ARVN stock opened at $19.08 on Friday. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -4.09 and a beta of 1.82. The firm has a 50-day moving average price of $24.20 and a 200 day moving average price of $25.34. Arvinas has a twelve month low of $17.37 and a twelve month high of $53.08.

Arvinas (NASDAQ:ARVN) last released its earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to analysts’ expectations of $60.56 million. During the same quarter last year, the company posted ($1.18) earnings per share. The business’s quarterly revenue was up 196.0% compared to the same quarter last year. As a group, research analysts predict that Arvinas will post -3.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ARVN. nVerses Capital LLC bought a new stake in shares of Arvinas in the 3rd quarter valued at about $39,000. Quest Partners LLC purchased a new position in Arvinas during the 2nd quarter valued at about $42,000. Amalgamated Bank lifted its holdings in shares of Arvinas by 29.6% during the second quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock valued at $59,000 after purchasing an additional 508 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares during the last quarter. Finally, Quantbot Technologies LP increased its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after buying an additional 2,601 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.